Mantle cell lymphoma presenting with lethal atraumatic splenic rupture
Frederick Eyerer; Juli-Anne Gardner; Katherine A. Devitt
Abstract
Keywords
References
1 Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710-25.
2 Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703-6.
3 Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. 439 p. (World Health Organization Classification of Tumours).
4 Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647-56.
5 Martín-Garcia D, Navarro A, Valdés-Mas R, et al. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma. Blood. 2019;133(9):940-51.
6 Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1− mantle cell lymphoma. Blood. 2013;121(8):1394-402.
7 Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555-62.
8 Torlakovic E, Nielsen S, Vyberg M. Antibody selection in immunohistochemical detection of cyclin D1 in mantle cell lymphoma. Am J Clin Pathol. 2005;124(5):782-9.
9 The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909-18.
10 Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790-5.
11 Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975-81.
12 Bernard M, Gressin R, Lefrère F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001;15(11):1785-91.
13 Shrestha R, Bhatt VR, Guru Murthy GS, Armitage JO. Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. Leuk Lymphoma. 2015;56(10):2759-67.
14 Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (Mipi) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-65.
15 Hoster E, Rosenwald A, Berger F, et al. Prognostic value of ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386-94.
16 Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia. 1998;12(8):1281-7.
17 Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89(6):2067-78.
18 Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol. 1997;15(4):1664-71.
19 Renzulli P, Hostettler A, Schoepfer AM, Gloor B, Candinas D. Systematic review of atraumatic splenic rupture. Br J Surg. 2009;96(10):1114-21.
20 Mason KD, Juneja SK. Spontaneous rupture of the spleen as the presenting feature of the blastoid variant of mantle cell lymphoma. Clin Lab Haematol. 2003;25(4):263-5.
21 Oinonen R, Franssila K, Elonen E. Spontaneous splenic rupture in two patients with a blastoid variant of mantle cell lymphoma. Ann Hematol. 1997;74(1):33-5.
22 Zieren J, Paul M, Scharfenberg M, Müller JM. The spontaneous splenic rupture as first manifestation of mantle cell lymphoma, a dangerous rarity. Am J Emerg Med. 2004;22(7):629-31.
23 Lunning MA, Stetler-Stevenson M, Silberstein PT, Zenger V, Marti GE. Spontaneous (Pathological) splenic rupture in a blastic variant of mantle cell lymphoma: a case report and literature review. Clin Lymphoma. 2002;3(2):117-20.
24 Strickland AH, Marsden KA, McArdle J, Lowenthal RM. Pathologic splenic rupture as the presentation of mantle cell lymphoma. Leuk Lymphoma. 2001;41(1–2):197-201.
25 Gazzo S, Felman P, Berger F, Salles G, Magaud J-P, Callet-Bauchu E. Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma. Haematologica. 2005;90(12):1708-9. PMid:16330452.
26 Rahman K, Subramanian PG, Mittal N, et al. Morphological spectrum of leukemic mantle cell lymphoma. Indian J Pathol Microbiol. 2012;55(1):66-71.
27 Gruszka-Westwood AM, Atkinson S, Summersgill BM, et al. Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. Genes Chromosomes Cancer. 2002;33(2):206-12.
28 Miao Y, Lin P, Wang W, Jeffrey Medeiros L, Lu X. Ccnd1-igh fusion-amplification and myc copy number gain in a case of pleomorphic variant mantle cell lymphoma. Am J Clin Pathol. 2016;146(6):747-52.
29 Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood. 1997;89(4):1421-9.
30 Yagmur Y, Kara IH, Aldemir M, Büyükbayram H, Tacyildiz IH, Keles C. Spontaneous rupture of malarial spleen: two case reports and review of literature. Crit Care. 2000;4(5):309-13.
31 Patel MI. Spontaneous rupture of a malarial spleen. Med J Aust. 1993;159(11-12):836-7. PMid:8264491.
32 Thomson WH. Diffuse lymphocytic lymphoma with splenic rupture. Postgrad Med J. 1969;45(519):50-1.
33 National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology B-cell lymphoms version 4. Plymouth Meeting, PA: NCCN; 2021 [cited 2021 May 7]. Available from:
34 Maeda-Sakagami Y, Tanaka Y, Koba Y, Shinzato I, Ishikawa T. Mantle cell lymphoma presenting with spontaneous splenic rupture. Rinsho Ketsueki. 2016;57(8):1018-25. PMid:27599418.
Submitted date:
08/19/2021
Accepted date:
10/04/2021
Publication date:
11/05/2021